Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Slides:

Advertisements

Similar presentations

Volume 53, Issue 3, Pages (March 2008)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 68, Issue 2, Pages (August 2015)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum John M. Fitzpatrick, Marc.

Volume 54, Issue 4, Pages (October 2008)

Volume 51, Issue 1, Pages (January 2007)

Volume 73, Issue 6, Pages (June 2018)

Volume 53, Issue 5, Pages (May 2008)

Volume 51, Issue 4, Pages (April 2007)

Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 2, Pages (February 2013)

Volume 189, Issue 1, Pages (January 2013)

Volume 52, Issue 3, Pages (September 2007)

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Towards Early and More Specific Diagnosis of Prostate Cancer

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 56, Issue 2, Pages (August 2009)

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 43, Issue 1, Pages (January 2003)

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 41, Issue 2, Pages (February 2002)

Richard C. Harkaway European Urology Supplements

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

Volume 74, Issue 5, Pages (November 2018)

Volume 53, Issue 1, Pages (January 2008)

Neal Shore European Urology Supplements

Volume 54, Issue 6, Pages (December 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

European Urology is “Your” Journal

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Axel Heidenreich European Urology Supplements

Highlighting Unmet Needs: Real Patients, Difficult Choices

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Manfred Wirth, Peter Iversen, David McLeod, William See

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Epidemiology and Demographics of Prostatitis

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Axel Heidenreich European Urology Supplements

Introduction European Urology Supplements

Presentation transcript:

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard, Rudolf Maibach European Urology Volume 43, Issue 1, Pages 28-30 (January 2003) DOI: 10.1016/S0302-2838(02)00539-0

Fig. 1 Correlation of prostate specific antigen (PSA) doubling time to objective response in patients with measurable metastases. Bars represent individual patients. Asterixes denote median values of PSA doubling time in each of the three response categories. European Urology 2003 43, 28-30DOI: (10.1016/S0302-2838(02)00539-0)